Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
Aim. To estimate ibrutinib efficacy in the treatment of first early CLL relapses and in patients with ≥ 2 lines of preceding therapy. Analysis of treatment results in patients with del(17p) and monitoring of minimal residual disease (MRD) and ibrutinib safety profile. Materials & Methods. The ana...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Russo |
| Хэвлэсэн: |
Practical Medicine Publishing House
2018-01-01
|
| Цуврал: | Клиническая онкогематология |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://bloodjournal.ru/index.php/coh/article/view/349 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|